Home Cart Sign in  
Chemical Structure| 1303420-67-8 Chemical Structure| 1303420-67-8

Structure of PLX5622
CAS No.: 1303420-67-8

Chemical Structure| 1303420-67-8

PLX5622

CAS No.: 1303420-67-8

PLX5622 is a highly selective brain-penetrant CSF1R inhibitor allowing for extended and specific microglial elimination, preceding and during pathology development.

4.5 *For Research Use Only !

Cat. No.: A1189464 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łË˶ÊÊ Inquiry Inquiry
5mg łÍó¶ÊÊ Inquiry Inquiry
10mg łďʶÊÊ Inquiry Inquiry
25mg łÇËʶÊÊ Inquiry Inquiry
50mg łÇóď¶ÊÊ Inquiry Inquiry
100mg łËîͶÊÊ Inquiry Inquiry
250mg łÿÇď¶ÊÊ Inquiry Inquiry
1g łÇËî§¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łË˶ÊÊ

  • 5mg

    łÍó¶ÊÊ

  • 10mg

    łďʶÊÊ

  • 25mg

    łÇËʶÊÊ

  • 50mg

    łÇóď¶ÊÊ

  • 100mg

    łËîͶÊÊ

  • 250mg

    łÿÇď¶ÊÊ

  • 1g

    łÇËî§¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PLX5622

CAS No. :1303420-67-8
Formula : C21H19F2N5O
M.W : 395.41
SMILES Code : CC1=CN=C(C2=C1)NC=C2CC3=C(N=C(C=C3)NCC4=CC(F)=CN=C4OC)F
MDL No. :MFCD32201039
InChI Key :NSMOZFXKTHCPTQ-UHFFFAOYSA-N
Pubchem ID :52936034

Safety of PLX5622

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of PLX5622

RTK

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Humanized APP mutant knock-in homozygote mouse model Oral 1.5 mg/kg body weight Daily for 3 weeks To test the effect of microglia depletion on tau propagation, results showed that PLX5622 significantly reduced tau propagation. PMC7986521
Mouse APPPS1-21 mouse model Diet Onvansertib 45 mg/kg, Alpelisib 25 mg/kg 5 days a week for 32 days To assess whether microglia are necessary for abx-induced astrocyte phenotypes by depleting microglia in APPPS1-21 male mice via treatment with a colony-stimulating factor 1 receptor (CSF1R) inhibitor (PLX5622) and vehicle control or PLX5622 and abx. Results showed that abx-mediated reduction in GFAP+ astrocytes, PAAs, and astrocytic C3 expression is independent of microglia, but abx-induced astrocyte morphological alterations are dependent on the presence of microglia. PMC10324210
Mice AppNL-F and AppNL-G-F knock-in mice Oral 20 mg/kg, 40 mg/kg Once daily for 4 weeks To study the effect of PLX5622 on microglial ablation in mice, results showed that partial ablation had a greater impact on synaptic function than complete ablation. PMC8281661
Mice 5xFAD mouse model Oral 0.3 and 1 mg/kg Single dose, observed for 90 minutes PLX5622 allows for sustained microglial depletion and identifies roles of microglia in initiating plaque pathogenesis. PMC6704256
Mice MTX chemotherapy-related cognitive impairment model Oral 20-50 µM 20-25 minutes PLX5622 restored Bdnf expression and cognitive function after MTX exposure by depleting microglia. PMC6697075
Mice Cnp-null mutant mice Oral 1200 ppm Daily for one month PLX5622 alleviated the catatonic symptoms of Cnp mutants by depleting microglia. PMC5785265
Mice Mouse hepatitis virus (MHV) infection model Oral 0.1 mg/kg Single injection To investigate the role of microglia in neurotropic viral infection, results showed that microglia were crucial during the early days after infection to limit MHV replication and subsequent morbidity and lethality. PMC5824854
Mice Diet 1200 ppm 5 weeks PLX5622 depletes microglia by inhibiting the colony stimulating factor 1 receptor (CSF1R). The experimental results showed that PLX5622 significantly restored the expression of synapse-associated proteins during BTZ exposure and reversed BTZ-induced cognitive dysfunction. PMC10262803

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.65mL

2.53mL

1.26mL

25.29mL

5.06mL

2.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories